-
Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Tuesday, March 25, 2025 - 9:50pm | 657Read More...The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at 18,271.86, while the Dow remained largely flat at 42,587.50. The S&P 500 edged up 0.2% to finish at 5,776.65. Amidst these fluctuations, certain stocks grabbed the attention...
-
Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY)
Tuesday, July 16, 2013 - 11:30am | 536Read More...Eli Lilly & Co. (NYSE: LLY) planned to go back to the drawing board with its new experimental Alzheimer’s drug, according Bloomberg. The drug, solanezumab, which was not successful with advanced Alzheimer’s patients, will be tested in patients who show signs of early stages of the disease...
-
Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)
Tuesday, July 2, 2013 - 8:58am | 628Read More...Things are starting to heat up in the already hot pharmaceutical sector – especially as it relates to mergers and acquisitions. Only days after Onyx Pharmaceuticals (NASDAQ: ONXX) said it rejected an $8.7 billion buyout offer from Amgen (NASDAQ: AMGN), according to Reuters, the company has...
-
Bank of America Merrill Lynch Maintains Buy on Merck & Co.
Tuesday, June 7, 2011 - 8:07am | 109Read More...Bank of America Merrill Lynch is out with its report today on Merck & Co. (NYSE: MRK), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "Merck offers a good mix of low valuation, track record of returning cash to shareholders, and pipeline optionality, in our view....
-
Bank Of America Raises PT To $29 On MRK
Monday, May 16, 2011 - 7:31am | 145Read More...Bank of America is raising its price target to $41 and is reiterating its Buy rating on Merck & Co. (NYSE: MRK), as investors begin to warm up to pharma stocks again. Says Bank of America, in the report, “With each of the 4 US Major Pharma stocks beating Q1 results and investors beginning to...
-
UPDATE: J.P. Morgan Raises PT on Merck & Co. to $44 (MRK)
Monday, May 2, 2011 - 7:21am | 86Read More...J.P. Morgan is out with its report today on Merck & Co. (NYSE: MRK), raising its PT from $42 to $44. In a note to clients, J.P. Morgan writes, "We are increasing our MRK sales and EPS estimates following strong 1Q/11 results. Our new estimates are toward the high end of the company's 2011...
-
Deutsche Bank To Hold 36th Annual Healthcare Conference Next Week
Wednesday, April 27, 2011 - 8:00am | 135Read More...According to Deutsche Bank, it will be holding its 36th Annual Healthcare Conference in Boston on May 2nd-4th. Top companies in the healthcare industry will be in attendance, Deutsche Bank explains, “The conference will feature senior managements from many of the leading healthcare companies as...
-
Positive Results in SHARP Trial for Merck & Co. (MRK)
Monday, November 22, 2010 - 9:28am | 84Read More...Deutsche Bank has published a company alert today on Merck & Co. following results of the SHARP trial. In a note to clients, Deutsche Bank writes, "The SHARP trial compared vascular/atherosclerotic outcomes with Vytorin 10/20 therapy to placebo in 9,400 chronic kidney disease patients (approx...
-
Merck Stabilizes After SHARP Results (MRK)
Monday, November 22, 2010 - 7:46am | 249Read More...Citigroup has published a research report on Merck & Co., Inc. (NYSE: MRK) after the company reported a 17% risk reduction on its Vytorin-treated chronic kidney disease (CKD) patients. In the report, Citigroup writes "The Study of Heart And Renal Protection (SHARP) involved 9,438- patients...
-
Merck Adding To Its List Of Late stage Revenue Generating Assets, Citigroup Reports
Wednesday, November 17, 2010 - 12:03pm | 70Read More...When Merck & Co. Inc. (NYSE: MRK) presents positive data for its cholesterol modulator anacetrapib data at AHA later today, it will add to its list of significant late stage (NDA/Ph-III) revenue generating assets, Citigroup reports. “We see upside to our 2010E-‘15E topline growth CAGR of +1.5...
-
Goldman Sachs Adjusts MHS And ESRX Estimates
Tuesday, November 16, 2010 - 8:51am | 131Read More...Goldman Sachs is adjusting its cash EPS reporting for Medco Health Solutions (NYSE: MHS) and Express Scripts Inc. (NASDAQ: ESRX) to exclude all amortization expenses (also legacy amortization) from its previous reporting methodology of only excluding Merck & Co. Inc. (NYSE: MRK)-related...
-
Citigroup Expects Big Things From Merck's New Osteoporosis Medication
Monday, October 18, 2010 - 7:55am | 79Read More...When Merck & Co., Inc. (MRK) announces its results for Odanacatib, a new inhibitor designed to combat osteoporosis, Citigroup is anticipating a positive announcement. “The favorable 4-year results are supportive of MRK's ongoing large Phase III trial that is expected to complete in 2012,”...
